Filter Results
Phase II Trial Data for Pevonedistat Drug Combination Encouraging
While the last few years have seen the arrival of new drugs for patients with acute myeloid leukemia (AML), including targeted drugs and immunotherapies, there is still an unmet need for novel drugs for patients with this disease (and its precursor, myelodysplastic syndrome [MDS]).
Combination Therapy Effective in IDH1-Mutated Acute Myeloid Leukemia
A combination therapy of ivosidenib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center.
QUAZAR Trial: Escalated CC-486 Dosing Safe After First AML Relapse
Escalating dosing with the experimental oral hypomethylating agent CC-486 appears to be safe and well-tolerated for patients experiencing first acute myeloid leukemia (AML) relapse, according to analysis of data from the QUAZAR AML-001 phase III clinical trial. (Abstract 7513).
Minority of Older AML Patients on Venetoclax Combo Have Extended Response
Venetoclax, a first-in-class drug that selectively binds and inhibits B-cell lymphoma-2 (BCL-2) protein, has garnered a lot of attention in the treatment of people with acute myeloid leukemia (AML).
Predicting Patient-Reported AML Outcomes With the FACT-Leu Scale in AML
Although patient-reported outcomes (PROs) predict overall survival (OS) in solid cancer populations, there is little evidence around the prognostic value of PROs in patients with acute myeloid leukemia (AML) and other hematologic malignancies.
QUAZAR Trial Finds CC-486 Also Safe for Older AML Patients
Most patients over 75 years of age who have successfully been treated for acute myeloid leukemia may safely continue on maintenance doses of the experimental drug CC-486 without experiencing any serious side effects, according to data from the QUAZAR AML-001 clinical trial, details of which were presented at the 2020 ASCO Annual Meeting (Abstract 7530).
New Combination Regimen Boosts AML Remission
Combined treatment with enasidenib and the hypomethylating agent azacitidine significantly improved complete remission (CR) and overall response rates (ORR) compared with azacitidine alone in a group of 101 newly diagnosed acute myeloid leukemia (AML) patients with an IDH2 mutation.
Positive Quality-of-Life Data Reported With CC-486 in AML Patients
Maintenance therapy with the experimental oral hypomethylating agent CC-486 resulted in very little change in health-related quality-of-life scores in older patients successfully treated for acute myeloid leukemia.